Fecal incontinence (FI) is the inability to control bowel movements, leading to involuntary leakage of stool. It affects approximately 1 in 12 adults worldwide, with a higher prevalence among women and older individuals. There is a high unmet clinical need for better therapies, as current treatment options, such as fiber supplements, antidiarrheal medications, and biofeedback therapy, offer limited efficacy. Emerging fecal incontinence drug candidates aim to address the condition’s underlying causes, driving advancements in treatment options.
Major companies involved in the fecal incontinence pipeline drugs market include Cook MyoSite, Cellf Bio LLC, and others.
Leading drugs currently in the pipeline include Iltamiocel, Botulinum Toxin A, and others.
The rising prevalence of fecal incontinence, limited effectiveness of existing treatments, and increasing investment in novel therapeutics are driving significant growth in the fecal incontinence pipeline to address unmet clinical needs.
The Fecal Incontinence Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into fecal incontinence therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for fecal incontinence. The fecal incontinence report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The fecal incontinence pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with fecal incontinence treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to fecal incontinence.
Fecal incontinence is the loss of bowel control, resulting in involuntary stool leakage. It can arise from weakened anal muscles, nerve damage, chronic constipation, or diarrhea. Contributing causes may include aging, childbirth injuries, strokes, or neurological disorders. Prompt diagnosis and management are essential for improving the quality of life.
Fecal incontinence treatments encompass dietary changes, pelvic floor exercises, and medications. Biofeedback enhances the strength of anal muscles, while surgery, such as sphincter repair or nerve stimulation, can help in severe cases. Absorbent pads can manage symptoms, with personalized care ensuring better outcomes.
Fecal incontinence affects approximately 1 in 12 adults worldwide, with a higher prevalence among women and the elderly. In the United States, it impacts around 7% to 15% of the population, while in England, over 6.5 million adults face challenges with bowel control, with 1 in 10 experiencing fecal incontinence. The development of new therapies and treatments within the drug pipeline aims to address these widespread concerns and improve the quality of life for those affected by this condition.
This section of the report covers the analysis of fecal incontinence drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total fecal incontinence clinical trials.
The drug molecule categories covered under the fecal incontinence pipeline analysis include monoclonal antibodies, small molecules, gene therapies, cell therapies, peptides, and others. The fecal incontinence report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for fecal incontinence.
The EMR report for the fecal incontinence drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed fecal incontinence therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in fecal incontinence clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for fecal incontinence. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of fecal incontinence drug candidates.
Iltamiocel, developed by Cook MyoSite, is an autologous muscle-derived cell (AMDC) therapy under investigation in a Phase III trial for chronic fecal incontinence in females with obstetric injury. The study aims to evaluate its efficacy and safety in reducing incontinence episodes. Iltamiocel, derived from a patient’s muscle cells, is injected into the anal sphincter to restore function, compared against a placebo in a double-blind design.
SMDC therapy utilizes a patient’s muscle cells to restore sphincter function. It is a part of a Phase III clinical study, sponsored by Innovacell AG. The trial is designed to evaluate the safety and efficacy of autologous skeletal muscle-derived cells (aSMDC) for fecal incontinence caused by external anal sphincter dysfunction. The trial, involving around 290 participants is expected to conclude in July 2026.
Botulinum Toxin A (Botox) is a neurotoxin that works by blocking the release of acetylcholine, a neurotransmitter responsible for muscle contraction. Shaare Zedek Medical Center is sponsoring an open-label pilot study to evaluate botulinum toxin A (Botox) for intractable non-retentive fecal incontinence (NRFI) in children. This early Phase I study aims to assess the drug’s efficacy and safety. Botulinum Toxin A, known for muscle relaxation, will be administered intra-rectally to reduce sphincter hyperactivity, with outcomes tracked over 15 weeks.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The fecal incontinence Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for fecal incontinence. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into fecal incontinence collaborations, regulatory environments, and potential growth opportunities.
Inflammatory Bowel Disease Treatment Market
Global Irritable Bowel Syndrome Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share